We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Philips and Ibex Expand Partnership to Enhance AI-Enabled Pathology Workflows

By LabMedica International staff writers
Posted on 25 Mar 2025
Print article
Image: Interoperable AI-powered digital pathology workflows support confident cancer diagnosis (Photo courtesy of Royal Philips)
Image: Interoperable AI-powered digital pathology workflows support confident cancer diagnosis (Photo courtesy of Royal Philips)

Royal Philips (Amsterdam, The Netherlands) has expanded its partnership with Ibex Medical Analytics (Tel Aviv, Israel) and released the new Philips IntelliSite Pathology Solution (PIPS) to further accelerate the adoption of AI-enabled digital pathology to address the pressure pathologists face because of the global shortage of pathologists and the growing number of cancer patients. Following the start of the partnership in 2021, Philips and Ibex can offer even further interoperability of its solutions, aiming to enhance diagnostic workflows for clinicians and enabling better care for more people.

Ibex's AI and Philips’ digital pathology solution have shown to improve reporting efficiency and drive productivity gains of up to 37%. Through this partnership, pathology laboratories are able to utilize PIPS, which includes the full portfolio of scanners and Image Management System, and Ibex’s platform of AI-powered tools for prostate, breast and gastric cancer diagnostics. Expanding access and streamlining the use of AI-powered tools in digital pathology will further enhance the efficiency and effectiveness of pathology labs. Enabling AI directly in digital pathology workflows empowers clinicians to generate objective, reproducible results, increasing diagnostic confidence and enabling the productivity improvements needed to address the growing demand for pathology-based diagnostics. By further integrating Ibex's AI with PIPS, the solutions can offer optimized workflows, including help with case prioritization, AI-powered cancer detection and reporting, providing easier integration of productivity enhancing tools for more confident diagnosis, supporting better patient care.

Philips is also introducing Philips IntelliSite Pathology 6.0, including several new features and AI capabilities into the system. By providing advanced analysis and insights based on the context of the scanned images, pathology teams can access a seamless, AI-powered clinical workflow solution, from case management through to diagnosis and reporting. PIPS 6.0 features improved workflows and enhancements including full scan mode for the pathology SG scanner and contextual launch of AI [2] and counter marker tool in the image management system, as well as improved scalability. AI focused worklists show AI processing status at a case level and slides can automatically be shared with Ibex AI applications, for processing right after digitization. This new version of the Philips digital pathology solution offers optimized workflows, designed to enhance the efficiency and improved patient care. Based on Philips’ collaboration with Amazon Web Services, offerings for cloud archival services will allow pathology labs to efficiently and securely store, manage, and analyze growing volumes of digital pathology data.

“Pathology provides key information for a precise diagnosis. The Philips and Ibex solutions are especially beneficial to the diagnosis of cancer cases because they aid our pathologists in making an accurate and quick diagnosis,” said Sam Terese, President & CEO of Alverno Laboratories. “These integrated pathology solutions help us provide the highest possible quality result that any lab can deliver, getting answers back to our clinicians quickly and saving patients sleepless nights, even on complex cases.”

“The enhanced interoperability between Philips and Ibex platforms, which are now more seamlessly integrated into our diagnostic workflows, will accelerate the adoption of augmented pathology tools in which we strongly believe,” said Stéphane Rossat, Innovation & Scientific Director and Project Management at Medipath. “PIPS 6.0 promises to facilitate adoption by our physicians, thanks to its streamlined navigation and optimized workflows. We are eager to contribute to the evolution toward true digital "cockpits," which will become the reference interface for our pathologists.”

Related Links:
Royal Philips
Ibex Medical Analytics

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.